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Aims: This study assessed the cost efficacy and cost utility of the automatic blood glucose 
meter CONTOUR® TS from the public payer (National Health Fund [NHF]) and payer (patient 
and NHF) perspectives over a 26-year analysis horizon.
Methods: Clinical effectiveness data were obtained from prior clinical studies of automatic 
versus manually coded blood glucose meters. Cost data were obtained from the NHF. The 
probability of procedure use related to diabetic complications was obtained from four medical 
centers in Poland. The incremental cost-effectiveness ratio related to 1 life year gained and the 
incremental cost-utility ratio related to 1 quality-adjusted life year gained were calculated.
Results: Assuming co-funding from public funds, introduction of the CONTOUR® TS is 
associated with savings of Polish złoty (PLN) 31,846.19 (€8916.93) and PLN 113,018.19 
(€31,645.09) per life year gained from the payer and public payer perspectives, respectively. Cost 
utility analyses showed that the CONTOUR® TS is associated with savings of PLN 40,465.59 
(€11,330.37) and PLN 11,434.82 (€3201.75) per quality-adjusted life year gained from the 
payer and the public payer perspectives, respectively.
Conclusion: The CONTOUR® TS appears superior to manually coded meters available in 
Poland both from the payer and the public payer perspectives and may represent an improved 
strategy for glycemic control.
Keywords: blood glucose self monitoring, costs and cost analysis, health care costs, diabetes 
mellitus, diabetes complications
Introduction
The worldwide prevalence of diabetes is increasing exponentially. In 1997, a reported 
120 million people were affected by diabetes, and by 2010, that number rose to 
approximately 285 million.1,2 In Poland alone, the prevalence rate of diabetes is 9.3%, 
or 2.7 million people.2 Patients with diabetes have an increased risk for cardiovascular 
disease, stroke, kidney dysfunction, and eye disease, among other complications.1 The 
risk of developing diabetic complications has been correlated with poor glycemic 
control. Glycemic variability, assessed by changes in glycosylated hemoglobin levels 
(HbA1C), was shown to predict the development of microvascular complications in 
patients with diabetes.3 For this reason, diabetes management schemes are primarily 
focused on normalizing blood glucose levels by intensive glucose-lowering therapy.
Intensive glucose-lowering therapy involving administration of insulin by daily 
injections or an external insulin pump using frequent blood glucose monitoring to guide 
insulin therapy was shown to reduce the risk for developing retinopathy by as much as 
76%.4 Improved glycemic control reduces the risk of acute and chronic complications Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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and is associated with an improvement in overall patient 
health.5,6 Additionally, improved glycemic control has been 
associated with a   reduction in use of health care services 
and hospital admissions related to diabetic complications, 
resulting in lower medical costs for patients with diabetes.7,8 
Successful glucose-lowering therapy depends on correct mea-
surement of blood glucose levels using blood glucose meters. 
Incorrect measurements can lead to incorrect insulin dosing, 
which could result in a severe hypoglycemic event requiring 
h  ospitalization or inappropriate control of glycemic levels.
The use of manually coded blood glucose meters is asso-
ciated with a higher incidence of incorrect measurements 
and concomitant administration of inappropriate insulin 
doses compared with automatic blood glucose meters.9 
In one clinical study10 of 193 patients with diabetes, 16% 
of patients using manually calibrated blood glucose meters 
miscoded them, resulting in significant errors in blood 
glucose measurements. Additionally, 17% of patients using 
manually coded blood glucose meters considered coding to be 
difficult, even after instruction. Alternately, 99% of patients 
using automatic blood glucose meters considered the use of 
the systems to be relatively simple.10
The CONTOUR® TS system, an automatic blood glucose 
meter, is the only blood glucose monitoring system available in 
the Polish market that is equipped with No Coding™ technol-
ogy and that corrects blood glucose levels for the hematocrit 
effect. However, among the more than 10 meters available, only 
manually coded glucose meters are co-funded by the National 
Health Fund, some of which do not   correct for the hematocrit 
effect. The improved efficacy of the CONTOUR® TS system 
for intensive glucose-lowering therapy compared with manually 
coded systems has been shown in three clinical studies.9–11 The 
purpose of the current study is to evaluate the effects of replac-
ing manually coded blood glucose meters with the CONTOUR® 
TS system in diabetes management schemes on the cost of 
patient care within an analysis horizon of 26 years using data 
from 2006–2007. The cost effectiveness and cost utility of the 
CONTOUR® TS system, which is assumed to be co-funded 
by the National Health Fund (NHF) as a reimbursed medical 
device, will be evaluated from the perspective of the public 
payer (NHF) and the payer (patient and NHF) as compared 
with manually coded blood glucose meters available in Poland. 
These analyses will take into account the relative cost of daily 
glucose monitoring and the effect of the analyzed meters on 
clinically relevant diabetic complications, which will be used 
to determine the number of life years and quality-adjusted life 
years gained by use of the CONTOUR® TS system.
Research design and methods
clinical effectiveness analysis
A systematic review of the literature was conducted, and 
three clinical studies9–11 were identified that evaluated the 
efficacy of automatic blood glucose meters compared with 
manual blood glucose meters. The data from these three 
clinical studies were used in evaluating the effects of auto-
matic versus manually coded blood glucose meters on life 
years gained and quality-adjusted life years. Two automatic 
blood glucose meters and three manually coded glucose 
meters were e  valuated for the correlated risk of adminis-
tering incorrect insulin dosages in the study by Raine and 
colleagues.9 These results were used in the Monte Carlo 
analysis to develop predictions of e  rroneous insulin admin-
istration associated with the use of an automatic glucose 
meter, incorrectly coded manual glucose meter, and correctly 
coded manual glucose meter. The effect of certain diabetic 
complications on patients’ quality of life was d  etermined in 
the study by Frank and colleagues,11 and these data were used 
for evaluating the quality of life for patients with diabetes. 
The age-dependent quality of life of the general population 
versus diabetic patients, reported in the Cost Effectiveness 
Analysis Registry Database at the Center for the Evaluation 
of Value and Risk in Health,12 was also used in quality of life 
analyses. The determined effects of hematocrit on the validity 
of blood glucose measurements using the CONTOUR® TS 
system were used in efficacy evaluations.11
cost analysis
Costs were analyzed separately from the perspective of the 
public payer (NHF) and the payer (NHF and patient). The 
cost of hospital procedures, medication, outpatient visits, 
and rehabilitation were obtained from the following sources 
developed by the NHF: the “List of active substances used 
in therapeutic (drug) schemes”; the “Catalogue of hospital 
services” (Appendix No. 2 to Ordinance No. 40/2007 of 
the President of the NHF of June 26, 2007); the “C  atalogue 
of Outpatient Services of the National Health Fund” 
(A  ppendix No. 1 to Ordinance No. 14/2007 of the President 
of the NHF of March 29, 2007); and the “Catalogue of 
T  herapeutic (Drug) Schemes” (Ordinance No. 11/2007 of 
the President of the NHF of March 16, 2007 and Ordinance 
No. 80/2006 of September 18, 2006). Per patient costs of 
reimbursement and medication for diabetes and related 
complications were obtained from the Ministry of Health 
Web site,13 and a  dditional product cost data were obtained 
from the M  edycyna Praktyczna portal.14 The cost of using Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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the CONTOUR® TS blood glucose meter was determined 
using information from Bayer. It was assumed, based on 
clinical experience, that each patient in the analyzed popu-
lation measured blood glucose levels once daily using the 
CONTOUR® TS system or a manually coded glucose meter. 
The cost per test strip to the public payer and the payer were 
assessed separately using the assumed retail price of Polish 
złoty (PLN) 47.81 (€13.39) per package of test strips for 
the CONTOUR® TS meter and the mean cost of a package 
of test strips for manually coded blood glucose meters sold 
in Poland over a 13-month period, which was weighted 
by the number of packages sold. These values were then 
used in cost-effectiveness and cost utility analyses. It was 
assumed that the cost of using a blood glucose meter would 
be reimbursed 100% to a reimbursement limit of PLN 47.81 
(€13.39). PLN were converted to Euros (€) at an exchange 
rate of PLN 1 = €0.28 (average rate in 2008).
Data on the percentage of patients undergoing medical 
procedures related to complications of diabetes, such as 
acute coronary syndrome, stroke, diabetic foot syndrome, 
diabetic retinopathy, nephropathy, and a serious hypergly-
cemic event requiring hospitalization, were obtained from 
four medical centers in Malopolska and from consultation 
with m  edical experts. The cost of therapy for the treatment 
of stable coronary disease following an episode of acute 
coronary syndrome was estimated based on the guidelines 
of the P  olish Cardiac Society, consultation with cardiolo-
gists, and data from the Medycyna Praktyczna Web site.14 
Since a 26-year time h  orizon was used in this analysis, 
costs and outcomes that were measured in a single year 
were discounted at a rate of 5% per year, according to the 
G  uidelines of the Health Technology Assessment   Agency.15 
The value of one point in settlements between service 
provider and public payer was assumed to be PLN 10.50 
(€2.94) for hospital procedures, PLN 7.80 (€2.18) for 
o  utpatient treatment, and PLN 0.90 (€0.25) for rehabilitation. 
The cost of p  harmacotherapy for patients following acute 
myocardial infarction included c  lopidogrel for 50% of the 
patients within the first year or ticlopidine for the remaining 
patients, along with beta-  blockers, statins, and angiotensin-
converting enzyme   inhibitors, which for the purposes of cost 
analysis were assumed to be carvedilol, simvastatin, and 
enalapril, respectively. For the cost of medication for acute 
coronary syndromes, it was assumed that the public payer 
would cover only the cost of abciximab therapy, at a cost of 
PLN 136.50 (€38.22) per 1 mg. Standard biostatistical and 
  epidemiological methods were used in all cost analyses.
cost effectiveness and cost  
utility analyses
Cost effectiveness was expressed as the incremental 
cost-effectiveness ratio (ICER) when manually coded blood 
glucose meters were replaced with the CONTOUR® TS system 
in diabetes management schemes, which was calculated as 
the ratio of the additional cost incurred in relation to 1 life 
year gained resulting from use of the CONTOUR® TS s  ystem. 
A threshold value of PLN 58,000 (€16,240), based on the 
annual cost of dialysis treatment, was assumed for cost 
effectiveness. Cost utility was expressed as the incremental 
cost-utility ratio (ICUR) when manually coded blood glucose 
meters were replaced with the CONTOUR® TS system in 
diabetes management schemes, which was calculated as the 
ratio of additional cost incurred by use of the CONTOUR® 
TS system in relation to 1 quality-adjusted life year. The 
threshold value for cost utility was calculated by correcting 
the threshold cost for 1 life year gained for the highest utility 
of the patients’ health state and was determined to be PLN 
76,000 (€21,280). Both cost effectiveness and cost utility 
were calculated from the perspectives of the public payer and 
the payer, with an analysis horizon of 26 years.
Modeling
The Markov process was used to evaluate the cost effective-
ness and clinical efficacy of the CONTOUR® TS system 
versus manually coded meters over a 26-year analysis 
  horizon, and the values obtained were enhanced by the Monte 
Carlo method simulation. The starting point of this analysis 
was assumed to be the introduction of patients to intensive 
glucose-lowering therapy requiring the use of a blood 
  glucose meter. The 26-year analysis horizon corresponds 
with the life expectancy of a patient with diabetes based 
on the average age (53 years) of patients with diabetes in 
Poland.16 In this analysis, the baseline size of the populations 
in the study (CONTOUR® TS system) and control (manually 
coded blood glucose meters available in Poland) groups was 
assumed to be equal. The model used in this study analyzed 
the fate of hypothetical patients in the study and control 
groups, based on the probabilities of specific clinical out-
comes associated with each of the analyzed systems, which 
were determined from data collected from clinical efficacy 
studies and epidemiological studies.
Based on data from the probability of measurement errors 
using automatically and manually coded blood glucose 
meters from the previously mentioned clinical study,9 the 
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with a uniform continuous distribution, was used to generate 
2500 “real” blood glucose level values. A hematocrit value, 
within the range of 0%–100%, was assigned to each “real” 
glucose concentration, and bias values were assigned to three 
different ranges of hematocrit values as follows: 0%–20% 
hematocrit had a bias level of 5.1%, 20%–70% had a bias of 
5.8%, and 70%–100% had a bias of 6.4%. The CONTOUR® 
TS system was attributed a within-run coefficient of varia-
tion (CV) of 6.0%. The CV , bias, and “real” blood glucose 
levels were used to calculate the glucose levels measured 
by the CONTOUR® TS system. The number of insulin 
units required by the patient was assigned to the “real” and 
measured blood glucose levels. The percentage of events in 
which insulin units were incorrectly assigned was calculated 
based on the CONTOUR® TS measurements, and this value 
was used to calculate percentages of patients with incorrect 
measurements using the CONTOUR® TS system or a manu-
ally coded blood glucose meter. According to clinical studies, 
approximately 16% of patients using manually coded blood 
glucose meters miscode them,10 and the probability of incor-
rect insulin dosing was calculated using this value. Using 
the ratio of percentage of measurements to probability, the 
percentage of measurement errors with the CONTOUR® TS 
system and the probabilities of errors for automatically and 
manually coded blood glucose meters were used to calculate 
the percentage of incorrect measurements associated with 
manually coded glucose meters, which allowed a direct 
comparison of the efficacy of the CONTOUR® TS system 
and manually coded blood glucose meters.
The change in blood glucose concentration weighted by 
the percentage of incorrect measurements was determined by 
assigning each measurement error a maximum difference in 
blood glucose concentration resulting from incorrect insulin 
dosing and assumed that 1 unit of insulin lowers glucose 
concentrations by 50 mg/dL. The change in the level of 
glycosylated hemoglobin resulting from erroneous insulin 
dosage, which was used to predict transitions between clinical 
states, was calculated using the values proposed by Goldstein 
and colleagues,17 correlating blood glucose concentration 
with HbA1C levels. The HbA1C change was calculated for 
patients using the CONTOUR® TS system or manually coded 
blood glucose meters. The HbA1C levels of patients using 
the CONTOUR® TS and those using manually coded blood 
glucose meters were calculated as the sum of the baseline 
HbA1C value, HbA1C change resulting from incorrect insulin 
dosing, and the value of HbA1C lowering due to intensive 
monitoring of blood glucose levels, as reported by Farmer 
and colleagues.18 A value of -0.17% HbA1C was assigned 
to the CONTOUR® TS system, and a value of -0.14% was 
assigned to manually coded blood glucose meters, reflecting 
the higher precision associated with the CONTOUR® TS 
s  ystem compared with manually coded meters. It is assumed 
that the patients with incorrectly measured blood glucose 
levels sought outpatient treatment twice as frequently as 
patients with correctly monitored glucose levels, increasing 
from one visit in 3 months to two visits in 3 months.
The Markov model is often used for simulating the 
clinical course and associated costs of chronic disease. The 
disease course is divided into clinical states, and the prob-
abilities of transitions between states and the costs related to 
individual states are designated. The Markov model used in 
this analysis included the following states: “no events”, which 
consisted of the substates “first year after acute coronary 
syndrome (ACS)”, “subsequent years after ACS”, “post-
amputation”, “post-end stage renal disease”, and “patients 
without diabetic complications”; “serious hypoglycemia”; 
“ACS”; “stroke”; “end stage renal disease”; “amputation”; 
“retinopathy”; and “death”. The HbA1C levels for the study 
and control groups were used to calculate the probabilities 
of transitions between states. Probabilities for transitions 
between states were calculated using the CORE model at the 
baseline point in analysis.19 In subsequent analysis cycles, 
the CORE model was used for the probabilities of serious 
hypoglycemic events, end-stage renal disease, amputation, 
re-amputation, retinopathy, or proliferative retinopathy, or 
the risk reduction of an event associated with a 1%   reduction 
in HbA1C, as reported by Stratton and colleagues20 and 
Molyneaux and colleagues,21 was used for the probabilities 
of acute coronary syndrome, stroke, all-cause death, and 
cardiovascular death to more accurately evaluate the effect 
of CONTOUR® TS reimbursement for the payer and public 
payer. In the Markov model used in this study, patients’ lives 
were divided into a series of 6-month cycles, and each patient 
could have only one health status and associated probability 
in a given cycle.
Each patient was assigned to the “no events” state, 
substate of “diabetics”, for introduction into the model. 
In subsequent cycles, patients could remain in their current 
state or transition to other states; however, patients in the 
“stroke”, “ACS”, “end stage renal disease”, “serious hypo-
glycemia”, or “amputation” state could not remain in those 
states for more than one cycle. The results of a clinical study20 
correlating the risk of ACS and stroke with HbA1C level was 
used to estimate the number of patients with ACS or stroke. 
The probabilities of diabetes-related deaths were calculated 
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mortality increase for patients with diabetes versus healthy 
individuals. The probabilities of diabetes-related deaths 
were reduced by 21% per each 1% reduction in HbA1C level 
as a result of intensive glucose-lowering therapy. There is 
no direct correlation between HbA1C level and the prob-
ability of transition from the “proliferative retinopathy” to 
the “blindness” state, so a constant risk of vision loss event 
was assumed, and the 6-month probability was calculated 
as 0.96%. The HbA1C level-dependent probability of serious 
hypoglycemia requiring hospitalization was calculated as 
0.462%, with an annual hypoglycemia risk of 0.231%.
Patients in the “No events” state were assigned to one of 
the following substates: “first year post-ACS,” “subsequent 
years post-ACS,” “post-amputation,” “post-end stage renal 
disease,” and “diabetics” (for patients without diabetic com-
plications). The number of surviving patients in all states in the 
study (CONTOUR® TS) and control (manually coded blood 
glucose meters available in Poland) groups were discounted 
and summed after all analyzed periods. The difference in 
the sum of discounted 6-month periods of life between the 
study and control groups represented the cumulative 6-month 
periods of life gained as a result of replacing manually coded 
meters with the CONTOUR® TS system. This value was 
divided by 2 to give the value of life years gained attributable 
to CONTOUR® TS monitoring. The determined life years 
gained accumulated within the 26-year analysis horizon were 
divided through the cohort size (10,000 patients) to obtain life 
years gained per standard patient. To estimate quality-adjusted 
life years gained, the additional life cycles gained were multi-
plied by the value of quality of life of patients within a given 
cycle and then discounted. These quality-adjusted life cycles 
were summed, transformed into annual values, and calculated 
per patient. The difference between the quality-adjusted life 
years for one patient in the study group and quality-adjusted 
life years for one patient in the control group was used to 
determine the additional quality-adjusted life years resulting 
from inclusion of the CONTOUR® TS system in diabetes 
management schemes.
Due to the higher precision of glucose measurement, 
which translates into a lower HbA1C level, patients in the 
study group will generate lower costs for therapy of   diabetic 
complications relative to patients in the control group. 
For that reason, costs related to patients being a specific 
state of the Markov model were calculated separately for 
patients using the CONTOUR® TS system and patients using 
manually coded meters. The costs related to treatment of 
patients in a specific state for 1 cycle, including hospitaliza-
tions, pharmacotherapy, outpatient visits, and rehabilitation, 
were considered in cost analyses. In this model, the values 
of d  iscounting rates were transformed into 6-month rates 
using the formula m = 1 - (1 - p)1/2, where p is the annual 
rate and m is the 6-month rate. The value of m was 2.53% for 
costs and effects. The Markov model was subject to internal 
validation, and the program code was analyzed for errors 
independently by two researchers.
Sensitivity analyses
Sensitivity analyses were performed to determine the effects 
of model variables, including age, glucose level, manually 
coded meter compared with CONTOUR® TS, discount 
rates for costs and effects, and price of test strips, on the 
cost-effectiveness and cost-utility results from the primary 
analysis. For sensitivity analysis, patients using both the 
CONTOUR® TS system and manually coded meters were 
assigned the same HbA1C reduction of -0.17% HbA1C, rather 
than the values of -0.17% HbA1C and -0.14%, which were 
used in the primary analysis for the CONTOUR® TS system 
and manually coded meters, respectively. This exclusion 
was applied in the primary analysis to account for the 
higher level of diabetic control achieved by patients in the 
  CONTOUR® TS group. The effect of lowering or increasing 
the patients’ age by 10 years relative to the age of 53 years, 
which was used in all primary analyses, was examined in the 
sensitivity analysis, and subpopulation analyses of the age 
groups 43–53 and 53–63 years were conducted. For sensi-
tivity analysis, the measured outcomes for CONTOUR® TS 
system were compared with those determined for the ACCU-
CHEK® Active System, the most commonly used blood 
glucose meter in Poland, rather than all manually coded blood 
glucose meters as in the p  rimary analysis. Discount rates 
of 0% per year were assumed for both costs and effects for 
sensitivity analysis according to the G  uidelines of the Health 
T  echnology Assessment Agency. For 2-way sensitivity 
analyses, the discount rate for costs was assumed to be 0% 
per year with a discount rate for effects of 5% per year, and, 
conversely, a discount rate for costs was assumed to be 5% 
per year with a discount rate for effects of 0% per year. Since 
the price of a package of test strips for the CONTOUR® TS 
system is variable, sensitivity analyses were conducted to cal-
culate threshold prices at which the CONTOUR® TS system 
is superior to the compared m  anually coded glucose meters. 
Threshold prices were calculated for following conditions: 
the retail price of test strips for the CONTOUR® TS system 
does not affect the reimbursement limit; the reimbursement 
limit is based on the retail price of a package of test strips 
for the CONTOUR® TS system; test strip packages are Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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reimbursed 100% by the NHF; and the compared test strip 
costs are for all test strips used in   manually coded meters 
available in the Polish market and for test strips used in the 
ACCU-CHEK® active system.
Results
clinical effectiveness analysis
Use of the CONTOUR® TS system was associated with 
significant (P , 0.0001 for both) increase in life years 
gained (0.0017 [standard deviation (SD) = 0.0002]) and 
quality-adjusted life years (0.0046 [SD = 0.0002]) per patient 
in the 26-year analysis horizon compared with manually 
coded blood glucose meters; the extrapolated effect on 
HbA1C levels was established to be a 0.09% difference. The 
C  ONTOUR® TS system was associated with a reduction in the 
incidence of certain diabetic complications, i  ncluding vision 
loss, amputation due to diabetic foot syndrome, and serious 
hypoglycemic events requiring h  ospitalization, compared 
with manually coded blood glucose meters. H  owever, a slight 
increase in the incidence of acute c  oronary syndrome events 
was noted among patients using the CONTOUR® TS system, 
likely resulting from the reduced mortality associated with 
use of this system.
cost analysis
The following costs were identified as significant from the 
public payer and payer perspectives: cost of products used 
in the treatment of diabetes and its complications; cost of 
outpatient visits related to diabetes and its complications; 
cost of therapy for stroke or acute coronary syndrome, 
including hospitalizations, medical procedures, abciximab 
and other pharmacotherapy, and rehabilitation; cost of 
therapy for end-stage renal disease, including hemodialysis 
or kidney transplant; cost of retinopathy treatment, including 
hospitalization and vitrectomy; cost of hospitalization due to 
serious hypoglycemia; and cost of diabetic foot syndrome, 
including amputations. The costs of various clinical proce-
dures associated with the treatment of these complications 
were assessed and are presented in Table 1. These costs, in 
addition to costs for pharmacotherapy and outpatient visits 
related to ACS, outpatient visits to a diabetes clinic (two visits 
in 6 months for patients with correctly measured blood glucose 
levels and four visits in 6 months for patients with incorrectly 
measured blood glucose levels), and the cost of daily blood 
glucose monitoring, assuming one strip used daily, were con-
sidered in determining the total cost of diabetes treatment per 
patient in the 26-year analysis h  orizon from the p  erspective of 
the public payer and the payer for the CONTOUR® TS system 
compared with manually coded blood glucose meters. The 
total cost of ACS status was determined to be PLN 15,715.65 
(€4400.38) and PLN 14,193.66 (€3974.23) from the 
p  erspective of the payer and the public payer, r  espectively. The 
cost of daily blood glucose monitoring from the p  erspective 
Table 1 costs associated with common interventions for select 
complications associated with diabetes
Treatment Total cost
PLN €
Acute coronary syndrome
    Hospitalization for invasive  
treatment
2200.00 616.00
    AcS without increased  
myocardial markers
1650.00 462.00
    Hospitalization in an  
intensive cardiac care unit
990.00 277.20
    Balloon coronoplasty  
without stenting
3850.00 1078.00
    coronoplasty with stenting 8800.00 2464.00
    introduction of intra-aortic  
contrapulsation
3960.00 1108.80
    endocavitary stimulation 660.00 184.80
    cardiac rehabilitation 2430.00 680.40
    Outpatient visit with primary  
care physician
57.00 15.96
    Type ii outpatient visit with  
cardiologist
39.90 11.17
    Type iii outpatient visit with  
cardiologist
69.83 19.55
Stroke
    Basic diagnostics and treatment 
(up to 3 days)
880.00 246.40
    extended diagnostics 1650.00 462.00
    Basic diagnostics and treatment  
(more than 3 days)
1980.00 554.40
    Treatment in a stroke ward  
(up to 3 days)
1980.00 554.40
    Treatment in a stroke ward  
(more than 3 days)
6600.00 1848.00
    Type ii outpatient visit with  
neurologist
133.00 37.24
    Type iii outpatient visit with  
neurologist
2970.00 831.60
    rehabilitation 2970.00 831.60
End-stage renal disease
    Hemodialysis 370.00 103.60
    Kidney transplant 1890.00 529.20
Blindness
    Vitrectomy 4305.00 1205.40
    Hospitalization 210.00 58.80
Diabetic foot syndrome
    Amputation of lower limb  
and/or toes
1354.50 379.26
    Prosthesis and two type ii  
outpatient visits
865.52 242.35
Serious hypoglycemic event
    Hospitalization  1360.00 380.80
Abbreviations: ACS, acute coronary syndrome; PLN, Polish złoty.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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of the payer was PLN 0.96 (€0.27) for CONTOUR® TS and 
PLN 1.04 (€0.29) for manually coded glucose meters. From 
the perspective of the public payer, the costs of daily glucose 
monitoring for CONTOUR® TS and manually coded blood 
glucose meters were both PLN 0.89 (€0.25). There was a 
significant (P , 0.005) cost benefit from the perspective of 
the public payer and a significant (P , 0.0001) cost benefit 
from the perspective of the payer derived from use of the 
CONTOUR® TS system versus manually coded blood glucose 
meters in diabetes management strategies (Table 2), which 
can most likely be attributed to the higher precision of the 
CONTOUR® TS system. The incremental costs of comparison 
of C  ONTOUR® TS with manually coded blood glucose meters 
for the public payer and the payer are PLN 52.99 (€14.84) and 
PLN 187.13 (€52.40), respectively, per patient in the 26-year 
analysis horizon.
cost effectiveness and cost  
utility analyses
When manually coded blood glucose meters are replaced 
by the CONTOUR® TS system in treatment schemes for 
patients with diabetes, the gain of an additional year of life 
is associated with a significant (P , 0.0001 for both) savings 
from the perspective of the public payer (PLN 31,846.19 
[SD = 873.28]; €8916.93) and the payer (PLN 113,018.19 
[SD = 8547.86]; €31,645.09). Similarly, the gain of an 
additional quality-adjusted year of life is associated with a 
significant (P , 0.0001 for both) savings for both the public 
payer (PLN 11,434.82 [SD = 433.92]; €3201.75) and the 
payer (PLN 40,465.59 [SD = 873.28]; €11,330.37) when the 
CONTOUR® TS system is substituted for manually coded 
blood glucose meters. These results showed the cost utility 
and cost effectiveness of the CONTOUR® TS system for 
glucose monitoring from the perspectives of the payer and 
public payer, based on the threshold values assumed for cost 
utility (PLN 76,000 [€21,280]) per quality-adjusted life year 
gained) and cost effectiveness (PLN 58,000 [€16,240]) per 
life year gained).
Sensitivity analyses
Results of sensitivity analyses from the perspective of the 
public payer and the payer are presented in Tables 3 and 4. 
Sensitivity analyses evaluating the effects of age, control, 
HbA1C reduction, and discount rate for costs and effects 
determined no changes to the conclusions of the primary 
analysis with respect to cost efficacy and cost utility as a result 
of these variables. Analysis of the effect of patient age on 
clinical efficacy (life years gained and quality-adjusted life 
years gained) indicated that the use of the CONTOUR® TS 
system may improve clinical outcomes for younger patients 
as compared with manually coded blood glucose meters. 
A significant effect on cost effectiveness and cost utility 
results was observed as a result of changing the value of the 
discount rate of costs and effects due to the long time horizon 
used in analysis; however, these effects did not change the 
overall conclusions of the primary analysis.
Sensitivity analyses were conducted to determine the 
threshold values at which the CONTOUR® TS system is 
superior to manually coded blood glucose in terms of cost 
to the public payer and the payer. Under the assumption that 
the cost of a package of test strips is limited by the retail 
price and the test strips are reimbursed 100% from public 
funds, the diabetes management scheme involving the use of 
the CONTOUR® TS system in Poland results in savings to 
the public payer and the payer to a threshold gross w  holesale 
price of PLN 42.47 (SD = 0.02; €11.89) and PLN 45.49 
(SD = 0.01; €12.74), respectively, in the analysis horizon of 
26 years. These values translate to threshold retail prices of 
PLN 49.27 (SD = 0.02; €13.80) and PLN 52.89 (SD = 0.01; 
€14.81) for the public payer and the payer, respectively, 
i  ndicating that even with an increase in the r  eimbursement 
limit for   CONTOUR® TS test strips, the diabetes m  anagement 
Table 2 Total cost of diabetes treatment per patient in the analysis horizon of 26 years from the perspective of the public payer 
(national Health Fund) and the payer (patient and national Health Fund)
CONTOUR® TS Manually coded meters Incremental cost
Cost to public payer per patient discounted  
to baseline state of analysis, mean (SD) 
  PLn -11,251.36 (5.16) -11,304.35 (6.94) -52.99 (3.88)
 € -3150.38 (1.44) -3165.22 (1.94) -14.84 (1.09)
Cost to payer per patient discounted to  
baseline state of analysis, mean (SD) PLN
  PLn -13,000.63 (7.69) -13,187.76 (9.20) -187.13 (2.77)
 € -3640.18 (2.15) -3692.57 (2.58) -52.40 (0.78)
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scheme involving CONTOUR® TS for blood glucose level 
measurement results in lower costs for both the public payer 
and the payer as compared with manually coded blood 
  glucose meters with an analysis horizon of 26 years. In a 
similar evaluation comparing the CONTOUR® TS system 
with the ACCU-CHEK® Active glucose meter, assuming the 
cost of a package of test strips is limited by its retail price 
and is co-funded 100% from public funds, the threshold retail 
price of a package of strips is PLN 49.28 (SD = 0.04; €13.80) 
and PLN 52.71 (SD = 0.03; €14.76) from the perspective of 
the public payer and the payer, respectively. Even with this 
increase in the reimbursement limit, diabetes management 
schemes involving the CONTOUR® TS system are   associated 
with reduced costs relative to the ACCU-CHEK® Active 
glucose meter. These sensitivity analyses showed no effect 
of the analyzed range of CONTOUR® TS test strip prices on 
the findings with respect to cost savings for the CONTOUR® 
TS system from the primary analysis.
Discussion
Poor glycemic control results in reduced clinical outcomes 
for patients with diabetes and subsequent increases in   medical 
costs related to the treatment of diabetic complications. 
Accurate blood glucose measurements are critical for the 
appropriate management of intensive blood glucose  lowering 
therapy and the associated reduction in complications and 
Table 3 Incremental cost, life years gained, quality-adjusted life years gained, incremental cost-effectiveness ratio (cost efficacy), 
and incremental cost-utility ratio (cost utility) results from 1- and 2-way sensitivity analyses for the payer (patient and national 
Health Fund)
Variable Incremental cost,  
mean (SD)
LYG QALY ICER ICUR, mean (SD)
PLN € PLN € PLN €
Age (43–53 years) -229.28  
(3.38)
-64.20  
(0.95)
0.0027  
(0.0003)
0.0068  
(0.0003)
-87,123.93  
(7006.67)
-24,394.70  
(1961.87)
-34,006.71  
(1152.43)
-9,521.88  
(322.68)
Age (53–63 years) -141.34  
(2.40)
-39.58  
(0.67)
0.0010  
(0.0001)
0.0027  
(0.0001)
-145,303.79  
(11,589.73)
-40,685.06  
(3245.12)
-52,137.85  
(1587.89)
-14,598.60   
(444.61)
control  
(AccU-cHeK® Active)
-179.86  
(2.94)
-50.36  
(0.82)
0.0016  
(0.0001)
0.0046  
(0.0002)
-111,848.71  
(7977.39)
-31,317.64  
(2233.67)
-39,442.49  
(1085.55)
-11,043.90   
(303.95)
HbA1c reduction  
(-0.17%)
-189.72  
(2.48)
-53.12  
(0.69)
0.0010  
(0.0001)
0.0038  
(0.0002)
-186,061.99  
(22,041.12)
-52,097.36  
(6171.51)
-50,166.38  
(1770.10)
-14,046.59   
(495.63)
Discount rate for costs  
(from 5% to 0%)
-289.74  
(4.08)
-81.13  
(1.14)
0.0017  
(0.0002)
0.0046  
(0.0002)
-175,388.87  
(12,808.73)
-49,108.88  
(3586.44)
-62,905.83  
(1998.97)
-17,613.63   
(559.71)
Discount rate for effects  
(from 5% to 0%)
-186.61  
(2.61)
-52.25  
(0.73)
0.0036  
(0.0003)
0.0090  
(0.0004)
-51,522.38  
(3338.54)
-14,426.27  
(934.79)
-20,739.50  
(563.51)
-5807.06  
(157.78)
Abbreviations: SD, standard deviation; PLN, Polish złoty; LYG, life years gained; QALY, quality-adjusted life years gained; ICER, incremental cost-effectiveness ratio;   
icUr, incremental cost-utility ratio.
Table 4 Incremental cost, life years gained, quality-adjusted life years gained, incremental cost-effectiveness ratio (cost efficacy), and 
incremental cost-utility ratio (cost utility) results from 1- and 2-way sensitivity analysis for the public payer (national Health Fund)
Variable Incremental cost,   
mean (SD)
LYG QALY ICER ICUR
PLN € PLN € PLN €
Age (43–53 years) -64.84  
(5.09)
-18.16  
(1.43)
0.0027  
(0.0003)
0.0068  
(0.0003)
-24,493.94  
(610.02)
-6858.30  
(170.81)
-9588.98  
(328.92)
-2684.91   
(92.10)
Age (53–63 years) -38.81  
(3.03)
-10.87  
(0.85)
0.0010  
(0.0001)
0.0027  
(0.0001)
-39,681.38  
(1,165.68)
-11,110.79  
(326.39)
-14,281.59  
(538.71)
-3998.85   
(150.84)
control  
(AccU-cHeK® Active)
-52.36  
(3.92)
-14.66  
(1.10)
0.0016  
(0.0001)
0.0046  
(0.0002)
-32,402.24  
(647.58)
-9072.63  
(181.32)
-11,456.80  
(432.73)
-3207.90   
(121.16)
HbA1c reduction  
(-0.17%)
-50.65  
(3.43)
-14.18  
(0.96)
0.0010  
(0.0001)
0.0038  
(0.0002)
-49,327.11  
(3,214.33)
-13,811.59  
(900.01)
-13,360.13  
(371.99)
-3740.84   
(104.16)
Discount rate for costs  
(from 5% to 0%)
-85.23  
(6.39)
-23.86  
(1.79)
0.0017  
(0.0002)
0.0046  
(0.0002)
-51,329.39  
(1126.02)
-14,372.23  
(315.29)
-18,457.32  
(626.62)
-5168.05   
(175.45)
Discount rate for effects  
(from 5% to 0%)
-52.21  
(3.49)
-14.62  
(0.98)
0.0036  
(0.0003)
0.0090  
(0.0004)
-14,358.94  
(311.28)
-4020.50  
(87.16)
-5791.81  
(192.33)
-1621.71   
(53.85)
Abbreviations: SD, standard deviation; PLN, Polish złoty; LYG, life years gained; QALY, quality-adjusted life years gained; ICER, incremental cost-effectiveness ratio;   
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medical costs. The cost efficacy and utility analyses of the 
CONTOUR® TS system showed that a diabetes manage-
ment scheme including use of the CONTOUR® TS system is 
superior to the use of manually coded blood glucose meters 
available in the Polish market from the perspective of the 
payer (patient and NHF) and the public payer (NHF). Clinical 
effectiveness analyses showed a small but significant gain 
of 0.0017 life years and 0.0046 quality-adjusted life years 
(equivalent to 0.6 days of life and 1.7 quality-adjusted days 
of life), in addition to a 0.09% improvement in HbA1C levels, 
over the analysis horizon of 26 years with the replacement 
of manually coded glucose monitors used in Poland with the 
CONTOUR® TS system. These effects may be more pro-
nounced when the CONTOUR® TS system is used in younger 
patients, as shown by the sensitivity analysis of age; although 
not evaluated in this study, there may be additional benefits 
for patients who have difficulty following manually coding 
procedures. The CONTOUR® TS system is also associated 
with a reduced risk of certain diabetic complications, includ-
ing vision loss, serious hypoglycemic event, and amputation 
of the lower limb or toes due to diabetic foot syndrome, when 
compared with manually coded blood glucose meters.
The medical costs associated with the treatment of com-
plications from diabetes are significantly greater than the costs 
of monitoring blood glucose levels. The higher precision of 
the CONTOUR® TS system is associated with lower costs 
of therapy related to diabetic complications compared with 
manually coded glucose meters. Additionally, results of this 
analysis showed a high cost effectiveness and cost utility 
for the CONTOUR® TS system relative to manually coded 
blood glucose meters. The economic benefits determined 
in this study for the CONTOUR® TS system may be more 
pronounced in clinical practice due to the additional   benefits 
of the system, such as compensation for the effects of   oxygen 
and maltose, which were not included in this analysis. 
Blood glucose measurements that correct for hematocrit   levels 
are considered more reliable. Hematocrit is the   percentage of 
erythrocytes in the blood and affects the reliability of blood 
glucose measurements. Higher hematocrit levels may cause 
glucose measurements to be lower than the actual values, and 
lower hematocrit levels may result in higher measurements 
than actual values. The CONTOUR® TS system corrects for 
hematocrit levels in a range of 0%–70%, which is the widest 
range of corrected hematocrit values among blood glucose 
meters available in Poland.
The Monte Carlo method used in this analysis is   considered 
highly reliable for evaluating the effects of a variable on the 
results of an analysis or on stability testing of results and 
  conclusions of the primary analysis, and the large sample 
size used permitted the demonstration of high repeatability 
and   statistical significance of the results. This method allowed 
patients with a wide range of blood glucose levels, from levels 
at the lower end of the diabetic range (∼150 mg/dL) to very high 
levels (∼450 mg/dL), to be considered in the analysis of the 
CONTOUR® TS diagnostic scheme, thereby offering a more 
accurate reflection of the effects of glucose-lowering therapy 
in the treatment of patients with diabetes. The Markov model 
used for calculation of clinical effects and costs related to the 
analyzed diagnostic schemes offers a reliable representation 
of the outcomes for patients using either the CONTOUR® TS 
system or manually coded glucose meters.
One limitation of the model is disregarding certain states of 
patients who had diabetic complications (nephropathy, diabetic 
foot, etc), due to the lack of a correlation between HbA1C level 
with the probability of transitions to these states. Addressing 
these issues in the future will elucidate the full benefit of the 
CONTOUR® TS system over the ACCU-CHEK® Active 
System. An additional limitation was assigning patients in 
each of the analyzed groups a constant HbA1C level throughout 
the 26-year analysis horizon. However, the clinical study23 
by Wiener and Roberts showed that there was no correlation 
between patient age and HbA1C levels. The reliability of the 
methods used in this analysis further strengthen the conclusion 
that use of the CONTOUR® TS system to replace manually 
coded blood glucose meters in diabetes management schemes 
is associated with a significant advantage with respect to cost 
utility and cost effectiveness from the perspectives of the payer 
and the public payer over a 26-year analysis horizon.
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